Skip to content

Vitamin B12 Status and Its Impact on Chronic Haemodialysis Patient

Vitamin b12 Deficency and Its Impact on Chronic Haemodialysis Patient and Its Effect on Anemia and Neuropathy

Status
Not yet recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT06441721
Acronym
Haemodialysis
Enrollment
60
Registered
2024-06-04
Start date
2024-07-05
Completion date
2025-09-01
Last updated
2024-06-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

End Stage Renal Disease on Dialysis, Vitamin B 12 Deficiency

Brief summary

To evaluate vitamin B12 level in haemodialysis patients and its impact on hematological and neurological manifestations

Detailed description

Vitamin B12 (cobalamin) is a water-soluble vitamin involved in several normal cellular functions (1). Vitamin B12 is required for the development, myelination, and function of the central nervous system; healthy red blood cell formation; and DNA synthesis (2- 4). Low levels of vitamin B12 have been associated with high concentrations of homocysteine (Hcy) and can lead to health complications (5). Hyperhomocysteinemia is an important risk factor for cardiovascular disease (6). Vitamin B12 and other B vitamins are involved in homocysteine metabolism, and researchers have hypothesized that supplementation with these micronutrients can reduce the risk of cardiovascular disease by lowering homocysteine levels (7, 8). Vitamin B12 deficiency is one of the causes of Macrocytic anaemia with increased mean corpuscular volume (MCV), defined as more than 100 fL, which is the hallmark of megaloblastic anaemia

Interventions

DEVICEVitamin b12 measure

Measure vitamin b12 in serum and its impact on Haemodialysis patient

Sponsors

Assiut University
Lead SponsorOTHER

Study design

Observational model
CASE_CONTROL
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to 80 Years

Inclusion criteria

* End stage renal disease on haemodialysis pts. * Parients more than 18 years . * CKD patients controled group stage 3and stage 4.

Exclusion criteria

* Recent renal transplantation patients. * Patients on sulpha drugs. * Patients on methotrexate. * Patients on anticonvulsant. * Patients on chemotherap agent. * Patients on colchicine. * Patients on bile acid sequestrant. * Patients on h2blockers. * Patients on metformin. * Patients on proton pump inhibitors . * Diabetic patients. * Parients with history of intestinal surgery. * Patients diagnosed with malabsorption syndrome. * Patient on vitamin b12 intake.

Design outcomes

Primary

MeasureTime frameDescription
vitamin b12 in serumone yearvitamin b12 evaluation vitamin b12 evaluation

Contacts

Primary ContactAfaf bakry amin, Resident
afafbakry79@gmail.com01093626639
Backup ContactAlaa Eldin Abd Elmoniem, supervisor
0106287922

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026